Now, Scottish compound management company BioAscent is launching ‘Compound Cloud’ – which they describe as ‘the Spotify of the drug discovery world’.
Organisations involved in the search for new drugs need a range of chemical compounds to test against their biological assays. In the past, these organisations were faced with either creating their own compounds, which is costly and time consuming, or buying fixed sets of compounds in large amounts, inevitably leading to wastage.
Compound Cloud offers affordable, customisable access to an IP-free former pharma compound library of chemicals, available in much smaller individual quantities. This will allow drug discovery organisations to potentially discover much more within a fraction of the time and at a lower cost.
Brand new to the market, this important new service will enable customers to have complete control over the content and format of their compound library to fit their exact needs – eliminating wastage and reducing storage space by offering ‘just in time’ global delivery of pre-plated sets containing just enough compound for an assay.
BioAscent predicts that high demand for this service will increase turnover for this part of their company by 300 percent over the next year, with three quarters of orders coming from overseas markets, including Europe, the USA and Canada.
Simon MacKenzie, BioAscent’s CEO said: “Compound Cloud was created after gathering extensive feedback from our customers. It provides simple, rapid and flexible access to quality compound libraries for drug discovery. It will allow customers to have complete control over their compound library, using our library as if it were their own.”
Glenn Crocker, Chief Executive of BioCity Group added: “Around 35% of early stage drug discovery projects in both industry and academia fail at the hit stage due to the poor structural properties of the compounds found through biological testing, which means there is no value to progressing these any further. This can be hugely frustrating for all involved, after what can be years of biological work. Compound Cloud is an exciting development which will help improve companies’ chances of drug discovery success, which is good news not just for the companies but for healthcare in general.”
Links